ImaRx Therapeutics Bolsters Executive Team.

TUCSON, Ariz. -- ImaRx Therapeutics, Inc., a biopharmaceutical company developing innovative solutions for stroke and vascular disease, today announced the appointments of Walter Singleton, MA, BM, B.Ch., as chief medical officer, and Lynne Weissberger, Ph.D., as vice president, regulatory affairs, quality assurance & regulatory compliance.

Singleton has more than 30 years' experience as a pharmaceutical industry executive, directing pre-clinical and clinical drug development, and managing partnerships in large and small company settings.

Weissberger has more than 15 years' experience in the pharmaceutical industry, serving as a liaison with the U.S. Food & Drug Administration and international regulatory agencies, and managing projects from pre-submission through commercialization.

Evan C. Unger, M.D., F.A.C.R., president and chief executive officer of ImaRx Therapeutics, said, "We are very fortunate to have Walter Singleton and Lynne Weissberger join our management team. They will play a key role as we enhance our product portfolio, expand our development programs, and move forward with clinical trials. As ImaRx moves into the next phase of its strategic plan, our success will largely depend on how well we manage our assets and exploit opportunities. Both Walter and Lynne have outstanding track records with some of the finest companies in our industry, and their expertise and skills will be a great contribution to the Company."

In addition to holding senior-level positions at a number of biotechnology and pharmaceutical companies, Singleton has served as a consultant on drug development and medical affairs through his own firm, New Drug Development Services. Previously, he was senior vice president, new drug development, for Chugai Pharma USA, responsible for designing and executing the strategy for developing the company's drug pipeline in the U.S. In addition, as Associate VP for International Development he was responsible for managing the progress of Chugai's multinational clinical programs. He has also held senior positions with Gensia Pharmaceuticals and Pfizer. He holds B.M. and B.Ch. degrees (equivalent to MD in the United States) from Oxford University Medical School, where he also received a Masters Degree in Animal Physiology.

Prior to joining ImaRx, Weissberger was senior director, regulatory affairs, at Myogen, Inc., where she managed the regulatory affairs department, and developed and implemented a company-wide quality assurance program. Her responsibilities included managing three global late-stage drug development programs. Previously, she was associate director, worldwide regulatory affairs, at Pfizer, Inc., where she was responsible for multiple IND, IDE and NDA submissions, and managed FDA relationships for several products. Her background also includes positions with Schein Pharmaceutical, Boots Pharmaceutical, and Parke-Davis/Warner Lambert Company. She received her doctorate in Human Nutrition/Physiology from Cornell University, and holds a Master of Education from Tufts University.

About ImaRx Therapeutics

The "Clotbusting" Company(TM).

ImaRx Therapeutics is utilizing groundbreaking medical technologies to develop products with the potential to revolutionize the treatment of stroke and vascular disease. ImaRx faces near-term commercial opportunities in addition to a deep pipeline of development stage compounds. At ImaRx, our goal is to improve patient outcomes by restoring critical blood flow to organs such as the brain, heart, and lungs following acute ischemic or thrombotic events through our innovative technology and products. The Company's research and development platform has extensive intellectual property protection that includes 114 issued US patents and 35 patent applications pending.

Forward-Looking Statement 

This release contains forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control, which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or other expectations implied by these forward-looking statements. These factors include results of current or pending research and development activities, actions by the Food and Drug Administration and other regulatory authorities, and the company's success in raising capital.